Rating Change
BTIG analysts reiterated a Buy rating on Cullinan Therapeutics, Inc. (NASDAQ:CGEM) on July 29, 2026.
reiterateNASDAQ:CGEM
BTIG Reiterates Buy Rating on Cullinan Therapeutics, Inc. (CGEM)
Rating Change BTIG analysts reiterated a Buy rating on Cullinan Therapeutics, Inc. (NASDAQ:CGEM) on July 29, 2026. Market Context Cullinan Therapeutics, Inc.
Market Context
Cullinan Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $17.51 with a market capitalization of $730.2M.
Analyst coverage from BTIG provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Cullinan Therapeutics, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Cullinan Therapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 29, 2026 | BTIG | Buy | N/A |
| Jun 11, 2026 | Wedbush | Outperform | N/A |
| Jun 08, 2026 | HC Wainwright & Co. | Buy | N/A |
| May 19, 2026 | BTIG | Buy | N/A |
| May 08, 2026 | Wedbush | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View CGEM Stock Page
Frequently Asked Questions
What does a Buy rating mean for CGEM?
A Buy rating from BTIG reflects the analyst's outlook on Cullinan Therapeutics, Inc. (NASDAQ:CGEM). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the CGEM forecast page.